Hidetaka Katabuchi

Hidetaka Katabuchi

Auto-generated profile, based on publicly available information

Hidetaka Katabuchi

Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
WYWataru Yamagami
Wataru Yamagami
SNSatoru Nagase
Satoru Nagase
FTFumiaki Takahashi
Fumiaki Takahashi
KIKazuhiko Ino
Kazuhiko Ino
THToru Hachisuga
Toru Hachisuga
HKHidetaka Katabuchi
Hidetaka Katabuchi
Yamagami W, et al. J Gynecol Oncol. 2016 Oct;28(2):e32. https://doi.org/10.3802/jgo.2017.28.e32

1 January 2020 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
WYWataru Yamagami
Wataru Yamagami
MMMikio Mikami
Mikio Mikami
SNSatoru Nagase
Satoru Nagase
TTTsutomu Tabata
Tsutomu Tabata
YKYoichi Kobayashi
Yoichi Kobayashi
DADaisuke Aoki
Daisuke Aoki
The Fourth Edition of the Guidelines for Treatment of Uterine Body Neoplasm was published in 2018. These guidelines include 9 chapters: 1. Overview of the guidelines, 2. Initial treatment for endometrial cancer, 3. Postoperative adjuvant therapy for endometrial cancer, 4. Post-treatment surveillance for endometrial cancer, 5. Treatment for advanced or recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment of uterine carcinosarcoma and uterine sarcoma, 8. Treatment of trophoblastic disease, 9. Document collection; and nine algorithms: 1-3. Initial treatment of endometrial cancer, 4. Postoperative adjuvant treatment for endometrial cancer, 5. Treatment of recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment for uterine carcinosarcoma, 8. Treatment for uterine sarcoma, 9. Treatment for choriocarcinoma. Each chapter includes overviews and clinical questions, and recommendations, objectives, explanation, and references are provided for each clinical question. This revision has no major changes compared to the 3rd edition, but does have some differences: 1) an explanation of the recommendation decision process and conflict of interest considerations have been added in the overview, 2) nurses, pharmacists and patients participated in creation of the guidelines, in addition to physicians, 3) the approach to evidence collection is listed at the end of the guidelines, and 4) for clinical questions that lack evidence or clinical validation, the opinion of the Guidelines Committee is given as a "Recommendations for tomorrow".

1 January 2021 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
HTHideki Tokunaga
Hideki Tokunaga
MMMikio Mikami
Mikio Mikami
SNSatoru Nagase
Satoru Nagase
YKYoichi Kobayashi
Yoichi Kobayashi
TTTsutomu Tabata
Tsutomu Tabata
HKHidetaka Katabuchi
Hidetaka Katabuchi
Tokunaga H, et al. J Gynecol Oncol. 2021 Feb;32(2):e49. https://doi.org/10.3802/jgo.2021.32.e49

28 June 2019 in Cancers
Verified
Journal Article
Open access
PDF file
TMTakeshi Motohara
Takeshi Motohara
HKHidetaka Katabuchi
Hidetaka Katabuchi
Epithelial ovarian cancer is a highly lethal gynecological malignancy that is characterized by the early development of disseminated metastasis. Though ovarian cancer has been generally considered to preferentially metastasize via direct transcoelomic dissemination instead of the hematogenous route, emerging evidence has indicated that the hematogenous spread of cancer cells plays a larger role in ovarian cancer metastasis than previously thought. Considering the distinctive biology of ovarian cancer, an in-depth understanding of the biological and molecular mechanisms that drive metastasis is critical for developing effective therapeutic strategies against this fatal disease. The recent “cancer stem cell theory” postulates that cancer stem cells are principally responsible for tumor initiation, metastasis, and chemotherapy resistance. Even though the hallmarks of ovarian cancer stem cells have not yet been completely elucidated, metastasized ovarian cancer cells, which have a high degree of chemoresistance, seem to manifest cancer stem cell properties and play a key role during relapse at metastatic sites. Herein, we review our current understanding of the cell-biological mechanisms that regulate ovarian cancer metastasis and chemotherapy resistance, with a pivotal focus on ovarian cancer stem cells, and discuss the potential clinical implications of evolving cancer stem cell research and resultant novel therapeutic approaches.

20 November 2017 in International Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TSToshiaki Saito
Toshiaki Saito
TTTsutomu Tabata
Tsutomu Tabata
HIHitoshi Ikushima
Hitoshi Ikushima
HYHiroyuki Yanai
Hiroyuki Yanai
HTHironori Tashiro
Hironori Tashiro
HKHidetaka Katabuchi
Hidetaka Katabuchi
Background Vulvar cancer and vaginal cancer are relatively rare tumors, and there had been no established treatment principles or guidelines to treat these rare tumors in Japan. The first version of the Japan Society of Gynecologic Oncology (JSGO) guidelines for the treatment of vulvar cancer and vaginal cancer was published in 2015 in Japanese. Objective The JSGO committee decided to publish the English version of the JSGO guidelines worldwide, and hope it will be a useful guide to physicians in a similar situation as in Japan. Methods The guideline was created according to the basic principles in creating the guidelines of JSGO. Results The guidelines consist of five chapters and five algorithms. Prior to the first chapter, basic items are described including staging classification and history, classification of histology, and definition of the methods of surgery, radiation, and chemotherapy to give the reader a better understanding of the contents of the guidelines for these rare tumors. The first chapter gives an overview of the guidelines, including the basic policy of the guidelines. The second chapter discusses vulvar cancer, the third chapter discusses vaginal cancer, and the fourth chapter discusses vulvar Paget’s disease and malignant melanoma. Each chapter includes clinical questions, recommendations, backgrounds, objectives, explanations, and references. The fifth chapter provides supplemental data for the drugs that are mentioned in the explanation of clinical questions. Conclusion Overall, the objective of these guidelines is to clearly delineate the standard of care for vulvar and vaginal cancer with the goal of ensuring a high standard of care for all women diagnosed with these rare diseases.

1 January 2024 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
MSManabu Seino
Manabu Seino
SNSatoru Nagase
Satoru Nagase
HTHideki Tokunaga
Hideki Tokunaga
WYWataru Yamagami
Wataru Yamagami
YKYoichi Kobayashi
Yoichi Kobayashi
MMMikio Mikami
Mikio Mikami
Seino M, et al. J Gynecol Oncol. 2023 Nov;35(1):e15. https://doi.org/10.3802/jgo.2024.35.e15